An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

Cicin, I.Oukkal, M.Mahfouf, H.Mezlini, A.Larbaoui, B.Slim, B. A.Uslu, R.Errihani, H.Alsalef, K.Belbaraka, R.Ozguroglu, M.Goktas, B.2019-10-272019-10-2720180959-80491879-0852https://doi.org/10.1016/S0959-8049(18)30535-5https://hdl.handle.net/11454/3047811th European Breast Cancer Conference (EBCC) -- MAR 21-23, 2018 -- Barcelona, SPAINen10.1016/S0959-8049(18)30535-5info:eu-repo/semantics/closedAccessAn open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant SettingConference Object92S102S103WOS:000429103100277Q1